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Abstract
Background: The European Randomized study of Screening for Prostate Cancer (ERSPC)
has previously demonstrated that prostate-specific antigen (PSA) screening decreases
prostate cancer (PCa) mortality.
Objective: To determine whether PSA screening decreases PCa mortality for up to 16 yr
and to assess results following adjustment for nonparticipation and the number of
screening rounds attended.
Design, setting, and participants: This multicentre population-based randomiseds 
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182 160 men, followed up until 2014 (maximum of 16 yr), with a predeﬁned core age
group of 162 389 men (55–69 yr), selected from population registry.
Outcome measurements and statistical analysis: The outcome was PCa mortality,
also assessed with adjustment for nonparticipation and the number of screening
rounds attended.
Results and limitations: The rate ratio of PCa mortality was 0.80 (95% conﬁdence
interval [CI] 0.72–0.89, p < 0.001) at 16 yr. The difference in absolute PCa mortality
increased from 0.14% at 13 yr to 0.18% at 16 yr. The number of men needed to be
invited for screening to prevent one PCa death was 570 at 16 yr compared with 742 at
13 yr. The number needed to diagnose was reduced to 18 from 26 at 13 yr. Men with
PCa detected during the ﬁrst round had a higher prevalence of PSA >20 ng/ml (9.9%
compared with 4.1% in the second round, p < 0.001) and higher PCa mortality (hazard
ratio = 1.86, p < 0.001) than those detected subsequently.
Conclusions: Findings corroborate earlier results that PSA screening signiﬁcantly
reduces PCa mortality, showing larger absolute beneﬁt with longer follow-up and a
reduction in excess incidence. Repeated screening may be important to reduce PCa
mortality on a population level.
Patient summary: In this report, we looked at the outcomes from prostate cancer in a
large European population. We found that repeated screening reduces the risk of
dying from prostate cancer.
© 2019 Published by Elsevier B.V. on behalf of European Association of Urology.
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The European Randomized study of Screening for Prostate
Cancer (ERSPC) was initiated in 1993, with the primary aim
to investigate the effect of regular prostate-specific antigen
(PSA) screening on prostate cancer (PCa) mortality. Findings
were previously reported on three occasions, as prespeci-
fied in the study protocol at 9, 11, and 13 yr of follow-up [1–
3]. The latest report (2014) showed that PSA screening
increased PCa incidence 1.6-fold and the relative reduction
in PCa mortality was 21% at 13 yr of follow-up [3]. This is the
16-yr main endpoint follow-up in order to quantify the
long-term harms and benefits of screening. Secondary aims
were to investigate how variations in screening attendance
and duration of screening (one test only vs repeated testing)
affected PCa mortality and whether this could explain the
observed variations in outcome between different screen-
ing trials as well as between different ERSPC centres [3,4].
2. Patients and methods
2.1. Study design and participants
The ERSPC, described previously [1–3], is a multicentre randomised
screening trial for PCa in eight European countries (Fig. 1). It started in
Belgium and the Netherlands (1993), and the last country to join was
France in 2003. Minor variations in screening protocols between centres
were accepted, but compulsory criteria for participation were deﬁned
[5], including PSA as the primary screening test, followed by systematic
prostate biopsies for men with elevated PSA; a core age group of men 55–
69 yr old at randomisation; repeated screening invitations; and regular
data delivery to an independent central database (age groups between
50 and 74 yr were invited in some centres). Stopping age for screening
invitations varied between 67 and 78 yr. Most centres used a 4-yr
interval, but Sweden and France used a 2-yr interval and Belgium a 7-yr
interval. A minimum of two and a maximum of eight invitations were
used for the core age group, and the duration of screening (time from the
ﬁrst to the last invitation) varied between 4 yr (oldest men in Finland)
and 16 yr (the Netherlands and Sweden). The primary screening tool was
PSA. To achieve high quality, a uniform PSA method was chosen (TandemPlease cite this article in press as: Hugosson J, et al. A 16-yr Follow-
Cancer. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.02.R; Hybritech). A quality assurance programme was designed to
guarantee accuracy of the test across centres. Additional screening
tools were employed in some centres. In the Netherlands, digital rectal
examination (DRE) was used during 1993–1996 in men with PSA 1.0–
4.0 ng/ml. In Finland, DRE was used in 1996–1998, and the ratio of free to
total PSA was used since 1999 in men with a PSA level of 3.0–3.9 ng/ml.
Since 1996, most centres used a PSA level of 3.0 ng/ml as the deﬁnition
of a positive screening test. Men with a positive screening test were
recommended DRE, transrectal ultrasound of the prostate, and
systematic prostate biopsies. Initially, sextant biopsies were the
standard, but this was later changed to 10–12 cores. A summary of
the characteristics by centre is provided in Table 1. French data were
excluded from the combined analysis, as these two centres failed to
comply with a primary criterion (screening participation >50%; Table 1)
[6]. Ethical approval was obtained separately for each participating
country.
2.2. Randomisation and masking
Two types of randomisations were used: randomisation before consent
(Zelen-type effectiveness design in Sweden, Finland, and Italy) and
randomisation after consent (efﬁcacy design in the other countries).
Randomisation was done by computer-generated random numbers, with
eligible participants identiﬁed in population registers. Trial group
allocation was masked for determination of the main outcome.
2.3. Outcomes
The primary outcome was PCa mortality. For deceased men with PCa,
medical records were evaluated by a cause of death (COD) committee
using a standardised ﬂow-chart to establish the COD [7]. The COD
committee was masked regarding the randomisation arm. Ofﬁcial CODs
were used in Finland since 2003 after demonstrating a very high
concordance with that obtained by the local COD committee [8]. PCa
incidence and vital status were monitored regularly in all randomised
men and reported biannually to the central database. For men with PCa,
TNM stage, PSA, Gleason score, and primary treatment were abstracted
from medical records. A scientiﬁc committee established quality criteria
and other committees monitored the conduct, progress of the trial, PSA
harmonisation, and assignment of Gleason grades [5]. This report
includes follow-up through December 31, 2014 or a maximum of 16 yr
after randomisation.up of the European Randomized study of Screening for Prostate
009
Fig. 1 – Trial profile (core age group). GS = Gleason score; M1 = evidence of metastases on imaging or PSA >100 ng/ml; PSA = prostate-specific antigen. a
Missing = missing T stage or GS, not M1 or PSA >100. b Low risk = T1, and T1 with GS 6. c Intermediate risk = T1, and T2 with GS 7 and T3 with GS 7. d
High risk = T1, T2, and T3 with GS 8–10 and T4 with any GS. e M1 or PSA >100, any T stage, or GS.
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2.4.1. Primary analysis
The primary analysis evaluated PCa mortality and focused on the core age
group of men 55–69–yr old, with follow-up through 2014 truncated at 9, 11,
13, and 16 yr. The main analysis was carried out according to the intention-
to-screen principle, that is, comparing groups formed by randomisation
(regardless of assignment compliance). Incidence and mortality rates, and
risks were calculated by dividing the number of events by the number of
person years and the number of men, respectively. Rate ratios (RRs; ratio of
incidence per person year), risk ratios (ratio of incidence per man), and the
corresponding differences were calculated using Poisson regression analysis,
with the control arm for Finland weighted by 1:1.5 due to unequal allocation
(agreed upon when Finland joined the trial). Conﬁdence intervals (CIs) for
rate and risk differences were calculated by Wald’s method, with standard
errors derived by the delta method. For the number needed to invite (NNI),
the CIs were derived as 1 over the intervals for the differences in the risk of
PCa mortality. The p values are two sided. No adjustment of signiﬁcance for
alpha-spending in sequential analyses was applied because the present
analysis is protocol based and not driven by statistical signiﬁcance [9,10]. The
NNI to avert one PCa death was calculated as the inverse of the absolute risk
difference in PCa deaths. The number needed to detect (NND) was deﬁned as
the NNI multiplied by the excess incidence of PCa in the screening group.
Both the graphs on cumulative PCa incidence and mortality in the control
and screening arms, and the graph on survival after screen-detected PCa are
based on Nelson-Aalen estimates of survival. Cumulative incidence and
mortality curves adjusted for the competing risk of death of other causes
follow the approach described in the study of Kalbﬂeisch and Prentice [11].
2.4.2. Secondary analysis
In a secondary analysis, PCa mortality was assessed from diagnosis in
those men diagnosed within the programme. Men with screen-detectedPlease cite this article in press as: Hugosson J, et al. A 16-yr Follow-u
Cancer. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.02.0cancer in round 1 were compared with screen-detected men during
subsequent screening rounds. Cox regression analysis was used.
To evaluate the effect of attending at least one screening round,
adjusted RRs were calculated with adjustment for nonparticipation
[12]. The proportion of complete nonattendees (ie, never participating)
in the screening group and the PCa mortality among them were
calculated. The control group is then considered to consist of a
nonattender part of the same size and the same PCa mortality rate as
the nonattender part of the screening group, allowing us to calculate the
adjusted mortality rate among those who participated at least once.
Additionally, we estimated an adjusted RR in men who attended at
least twice. Here, we deﬁned two groups of attendees: (1) all men who
participated only once and (2) men participated at least twice. The
proportion of men attending one screening round only and the PCa
mortality in this group were calculated. The underlying PCa mortality in
this group (screened only once) in the absence of screening is unknown,
but a recent study showed no effect of one screening round only [4]. We
therefore carried out analyses based on mortality reductions of 0% (there
was no beneﬁt to men with cancer detected at the ﬁrst screen) up to 25%
(ie, the beneﬁt of the ﬁrst screening was the same as that at later
screening round) in men screened only once. This trial is registered with
Current Controlled Trials (number ISRCTN49127736).
Statistical analyses were performed in R Statistical Software (version
3.3.1; Foundation for Statistical Computing, Vienna, Austria).
3. Results
3.1. Primary analyses
A total of 182 160 men were randomised, of whom
162 389 were part of the core age group of men 55–69 yr
old. Figure 1 shows the trial profile. Men randomised to thep of the European Randomized study of Screening for Prostate
09
Table 1 – Characteristics of the study overall and by centre
Belgium Finland Italy The Netherlands Spain Sweden Switzerland Total (excl. France) France, Herault France, Tarn Total
Age at
randomisation,
(yr), median (IQR)
63 (60.2, 66.2) 59 (54.8, 62.7) 62 (58.4, 65.9) 62 (58.0, 65.6) 60 (57.4, 64.2) 60 (57.2, 62.4) 61 (57.8, 65.1) 60 (57.1, 64.2) 62 (58.8, 65.9) 62 (57.9, 66.1) 61 (57.9, 65.0)
Randomised (n) 8562 80 379 14 515 34 833 2197 11852 9903 162 241 57 643 21 350 241 234
Screening, n (%) 4307 (50%) 31 970 (40%) 7265 (50%) 17443 (50%) 1056 (48%) 5901 (50%) 4948 (50%) 72 890 (45%) 28 784 (50%) 10 879 (51%) 112 553 (47%)
Control, n (%) 4255 (50%) 48 409 (60%) 7250 (50%) 17 390 (50%) 1141 (52%) 5951 (50%) 4955 (50%) 89 351 (55%) 28 859 (50%) 10 471 (49%) 128 681 (53%)
Follow-up (yr),
median (IQR)
16 (11.1, 16.0) 16 (13.8, 16.0) 15 (13.2, 16.0) 16 (13.8, 16.0) 16 (15.1, 15.9) 16 (13.9, 16.0) 13 (11.6, 14.2) 16 (13.0, 16.0) 9 (8.9, 9.6) 11 (9.8, 10.5) 13 (9.5, 16.0)
Screened at least
once, n (%)
3908 (91%) 23 771 (74%) 5730 (79%) 16 502 (95%) 1056 (100%) 4484 (76%) 4810 (97%) 60 261 (83%) 8121 (28%) 4143 (38%) 72 525 (64%)
Screening tests
done (n)
6446 52 142 12 731 40 358 1846 15 475 12 068 141066 10 060 5358 156 484
Screening rounds
per man (mean)
1.5 1.6 1.8 2.3 1.7 2.6 2.4 1.9 0.3 0.5 1.4
Positive tests (n) 1058 5925 1443 9552 354 2896 2599 23 827 1627 821 26 275
Men with positive
tests, n (%)
914 (21%) 4635 (14%) 1054 (15%) 6793 (39%) 326 (31%) 1537 (26%) 1729 (35%) 16 988 (23%) 1560 (5%) 760 (7%) 19 308 (17%)
Biopsies (n) 752 5404 902 8541 263 2509 2027 20 398 468 418 21 284
Biopsies/positive
tests (%)
71.1 91.2 62.5 89.4 74.3 86.6 78.0 85.6 28.8 50.9 81.0
Men with biopsy at
least once, n (%)
684 (75%) 4336 (94%) 741 (70%) 6187 (91%) 244 (75%) 1430 (93%) 1494 (86%) 15 116 (89%) 468 (30%) 410 (54%) 15 994 (83%)
Prostate cancer cases, screening group
Prostate cancer
cases overall in
screening group,
total (n)
482 3500 560 2376 92 814 620 8444 1718 747 10 909
Screen-detected
cancers (n)
188 1632 197 1868 60 576 436 4957 229 128 5314
Interval cancers
and cancers among
nonattendees (n)
294 1868 363 508 32 238 184 3487 1489 619 5595
Screen-detected
cancers/biopsy (%)
25.0 30.2 21.8 21.9 22.8 23.0 21.5 24.3 48.9 30.6 25.0
Cumulative
incidence in
screening group
(%)a
11.2 11.0 8.0 13.6 8.7 13.8 12.6 11.7 6.0 6.9 9.8
Prostate cancer cases, control group
Prostate cancer
cases overall in
control cohort,
total (n)
393 4546 452 1325 60 592 364 7732 1541 690 9963
Cumulative
incidence in
control group (%)a
9.2 9.4 6.5 7.6 5.3 9.9 7.4 8.7 5.4 6.6 7.8
IQR = interquartile range; PCa = prostate cancer.
a Calculated as total cases/randomised, excluding patients with PCa before randomisation.
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Fig. 2 – Prostate cancer incidence estimated by (A) the Nelson-Aalen approach and (C) the competing risk approach, and prostate cancer-specific
mortality estimated by (B) the Nelson-Aalen approach and (D) the competing risk approach. PC = prostate cancer.
E U R O P E A N U R O L O G Y X X X ( 2 0 1 9 ) X X X – X X X 5
EURURO-8274; No. of Pages 9screening arm were screened on average 1.94 times
(2.3 times in screening attendees), and of those participat-
ing, 28% were screen positive at least once (Table 1). Median
follow-up (excluding France; from randomisation to a
minimum of 16 yr, December 31, 2014, and the date of
death) was 15.5 yr and median follow-up from diagnosis to
PCa cases was 8.8 yr in the screening arm (10.3 in screen
detected and 4.5 in clinically detected) compared with
5.4 yr in the control arm. Cumulative PCa-specific incidence
at 16 yr was 13.3% in the screening arm and 10.3% in the
control arm (Nelson-Aalen estimates) (Fig. 2). Hence, PCa
incidence in the control arm compared with the screening
arm increased during longer follow-up; however, the
incidence still remained 1.4-fold higher in the screening
arm after 16 yr (Table 2).
The RR of PCa mortality between the arms was 0.80 at 16 yr
(95% CI 0.72–0.89, p < 0.001) and did not change compared
with 9, 11, and 13 yr of follow-up (Table 3). The absolute
difference between the trial arms increased from 0.14% at 13 yr
to 0.18% at 16 yr. The NNI was 570 and NND was 18 men
(Table 3). PCa mortality by age at randomisation (5-yr age
groups) is presented in Supplementary Table 1. Of the
individual centres, a significant mortality reduction was seen
in Sweden (RR 0.63, 95% CI 0.44–0.88, p = 0.008) and thePlease cite this article in press as: Hugosson J, et al. A 16-yr Follow-u
Cancer. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.02.0Netherlands (RR 0.67, 95% CI 0.53–0.85, p = 0.001; Supplemen-
tary Table 2). Supplementary Table 3 shows the distribution of
PSA levels at diagnosis in the different screening rounds.
3.2. Secondary analyses
PCa-specific survival for cases detected during the first
screening round was significantly worse compared with
those diagnosed at subsequent screening rounds (hazard
ratio = 1.86, p < 0.001; Fig. 3). The PCa mortality reduction
in those who attended at least one screening round was 25%
(RR 0.75, 95% CI 0.66–0.75). The calculated PCa mortality
reduction for those attending the screening programme at
least twice was 48% (RR 0.52, 95% CI 0.42–0.63) if no
mortality reduction was postulated from one test only, 43%
(RR 0.57, 95% CI 0.47–0.70) if a mortality reduction of 10%
was postulated, and 25% (RR 0.75, 95% CI 0.60–0.92) if first
screening was as effective as the following rounds
(Supplementary Table 4).
4. Discussion
This ERSPC update with 3 additional years of follow-up
shows that the absolute reduction in PCa mortality stillp of the European Randomized study of Screening for Prostate
09
Table 2 – Prostate cancer incidence at various lengths of follow-up
Years 1–9 Years 1–11 Years 1–13 Years 1–16
Screening group
Prostate cancer (n) 6172 6852 7655 8444
Person years 584 776 695 850 797 774 918 300
Rate per 1000 person years 10.55 9.85 9.60 9.20
Risk per 1000 men 85.16 94.54 105.62 116.51
Control group
Prostate cancer (n) 4154 5333 6384 7732
Person years 735 777 877 302 1 007 337 1 162 062
Rate per 1000 person years 5.65 6.08 6.34 6.65
Risk per 1000 men 46.71 59.97 71.79 86.95
Rate ratio (95% CI) 1.90 (1.83–1.98) 1.65 (1.59–1.71) 1.54 (1.49–1.59) 1.41 (1.36–1.45)
Rate difference per 1000 person years (95% CI) 5.00 (4.69–5.31) 3.86 (3.58–4.14) 3.35 (3.09–3.61) 2.66 (2.42–2.90)
Risk ratio (95% CI) 1.85 (1.78–1.93) 1.60 (1.54–1.66) 1.49 (1.44–1.54) 1.36 (1.32–1.41)
Risk difference per 1000 men (95% CI) 39.15 (36.65–41.65) 35.41 (32.71–38.12) 34.82 (31.93–37.72) 31.15 (28.05–34.25)
CI = conﬁdence interval.
Table 3 – Prostate cancer mortality at various lengths of follow-up
Years 1–9 Years 1–11 Years 1–13 Years 1–16
Screening group
Prostate cancer deaths (n) 191 268 371 520
Person years 612 723 735 205 848 802 985 382
Rate per 1000 person years 0.31 0.36 0.44 0.53
Risk per 1000 men 2.64 3.70 5.12 7.17
Control group
Prostate cancer deaths (n) 280 419 570 793
Person years 749 801 899 370 1 038 723 1 207 411
Rate per 1000 person years 0.37 0.47 0.55 0.66
Risk per 1000 men 3.15 4.71 6.41 8.92
Rate ratio (95% CI) 0.84 (0.70–1.00) 0.78 (0.67–0.91) 0.79 (0.69–0.90) 0.80 (0.72–0.89)
p value 0.053 0.001 <0.001 <0.001
Rate difference per 1000 person years (95% CI) 0.06 (0.12 to 0.00) 0.10 (0.17 to 0.04) 0.12 (0.18 to 0.05) 0.13 (0.20 to 0.07)
Rate ratio, attenders 0.78 (0.63, 0.96) 0.72 (0.60, 0.86) 0.73 (0.63, 0.85) 0.75 (0.66, 0.85)
p value 0.022 <0.001 <0.001 <0.001
Risk ratio (95% CI) 0.84 (0.70–1.00) 0.78 (0.67–0.91) 0.79 (0.70–0.90) 0.80 (0.72–0.90)
Risk difference per 1000 men (95% CI) 0.51 (1.04 to 0.01) 1.04 (1.67 to 0.41) 1.35 (2.09 to 0.61) 1.76 (2.63 to 0.88)
NNI (95% CI) 1947 (963–inf) 962 (598–2463) 742 (478–1650) 570 (380–1137)
NND 76 34 26 18
CI = conﬁdence interval; inf = inﬁnity; NND = number needed to invite to diagnose to prevent one prostate cancer death; NNI = number needed to invite to
screening to prevent one prostate cancer death.
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relative risk reduction remains unchanged at 20% since the
initial report based on 8.8 yr of follow-up [1–3]. PCa
incidence in the control group is gradually catching up
with the screening arm, but at 16 yr, a 41% excess incidence
remains in the screening arm. Results illustrate that both
incidence and mortality differences continue to change
between the two arms, and demonstrate why extended
follow-up is required to better understand the long-term
risks and benefits of PCa screening [13]. Despite a median
follow-up of 15.5 yr from randomisation, median follow-up
from diagnosis (ie, 8.8 yr in the screening arm and 5.4 yr in
the control arm) is quite modest given the natural course of
PCa, as many screening-detected cancers are of low or
intermediate risk with a long natural course [14]. Deaths
among men with PCa diagnosed after screening terminationPlease cite this article in press as: Hugosson J, et al. A 16-yr Follow-
Cancer. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.02.will also affect the long-term impact of the screening trial,
which will be observed in future follow-up.
The NNI to prevent one PCa death was 570 at 16 yr
compared with 1947 at 9 yr and 742 at 13 yr [1–3], an
important decrease, emphasising the long-term impact of
PCa screening. These figures differ from earlier publications,
as in our first two, where no truncation was performed at
9 and 11 yr.
The number of cases needed to diagnose for averting one
PCa death is declining from 48 in our first report at 9 yr to
18 in this update at 16 yr. With extended follow-up, the
NND will likely continue to decrease. Although it is difficult
to compare screening programmes, at 16 yr, the NND in the
Swedish centre was as low as 7 and comparable with that of
breast cancer [15]. Nevertheless, the considerable NND
reflects the abiding high excess incidence among screenedup of the European Randomized study of Screening for Prostate
009
Fig. 3 – Prostate cancer-specific survival in those detected during round 1 screening and those detected during repeated screening.
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with many years of follow-up. The continued decline in
NND many years after termination of PCa screening also
reflects the long lead time of screen-detected PCa [16].
For screening decisions, this long symptom-free period
has to be considered relative to early treatment with
immediate side effects that might negatively affect the
quality of life [17].
To detect roughly 5000 cancers, >20 000 biopsies were
performed, corresponding to a positive predictive value ofPlease cite this article in press as: Hugosson J, et al. A 16-yr Follow-u
Cancer. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.02.024%, and a quarter of participants were biopsied at least
once, demonstrating the low specificity of PSA as a
screening test. Development and use of more specific tests
such as Prostate Health Index, 4 K score, and risk calculators
must be prioritised, as well as improving the diagnostic
work-up with less invasive diagnostic methods such as
magnetic resonance imaging [18].
As in previous publications, we found a large difference
in PCa mortality reduction between centres within ERSPC,
with the largest effect observed in Sweden and thep of the European Randomized study of Screening for Prostate
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show a relative reduction in PCa mortality by approximately
35%. With different screening protocols and screening
lengths between centres, outcomes were evaluated by the
number of screening rounds. PCa mortality in men
diagnosed in the first screening round had a significantly
worse outcome compared with those detected at subse-
quent rounds (Fig. 3). One explanation is that many men
diagnosed in the first screening round had incurable
disease, whereas this was much less common in men
detected at subsequent screening rounds. This is supported
by the finding that the number of cancers detected with a
PSA level of >20 ng/ml was 182 (10% of all PCa cases
detected in that screening round) in round 1, 72 (4.1%) in
round 2, and only 42 (3.2%) in round 3 (Supplementary
Table 3). As PCa with a PSA level of >20 ng/ml to a high
degree represents incurable PCa, our data show that the
majority of such cancers were in fact diagnosed during the
first screening round. In this analysis, interval cancers were
not added to the cancer cases designated to round 2 or 3,
which could be questioned. However, the rate of aggressive
interval cancers is rare in PCa screening, and incorporation
of these cases into the calculations will change the overall
result only marginally [19].
These results suggest that a possible small beneficial
effect of one-time screening may only “drown” in the high
mortality rate of existing prevalent incurable PCa cases,
while repeated screening over long duration is necessary for
achieving a substantial and measurable PCa mortality
reduction. Several lines of evidence support this view.
Cases detected within ERSPC during the first round
frequently developed metastasis later, indicating that many
of these men diagnosed during the first round were
detected too late and screening could not prevent disease
progression [20].
A screening trial (Stockholm, 1988–1989) invited
2400 men aged 55–70 yr only once and found no difference
in PCa mortality after 20 yr from a nonscreened source
population; however, statistical power was limited
[21]. Similar results were observed in the present study:
men aged 70–74 yr were invited only once, and in this age
group, no effect on PCa mortality was seen (Supplementary
Table 1). No PCa mortality reduction was shown after 15 yr
in the US PLCO trial, which applied only 6 yr of screening
[22]. Despite several other components of this study may
explain the PLCO null result, including large control group
contamination, the short screening period may have
contributed [23,24]. Within ERSPC, Finland showed only a
small mortality reduction (RR 0.91) compared with the
Netherlands (RR 0.67) and Sweden (RR 0.63). In Finland, the
oldest age group where a quarter of the men were invited
only twice, the mean number of screening visits was 1.6. In
the Netherlands, all men in the core age group were invited
at least three times and the youngest up to five times, with
on average 2.3 screening visits. In Sweden, all men were also
invited at least three times and the youngest eight times,
with on average 2.6 screening visits. The results from these
three larger centres in ERSPC with different screening
intensity indicate that the length and intensity of screeningPlease cite this article in press as: Hugosson J, et al. A 16-yr Follow-
Cancer. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.02.are directly correlated to mortality reduction (Table 1). The
recently published CAP study invited 189 386 cluster-
randomised men to one-time screening, of whom 40%
participated. They found no significant effect on PCa
mortality (RR 0.96, CI 0.85–1.08; average follow-up 10 yr)
[4]. The data encouraged us to analyse the effect of repeated
screening rounds assuming various effects from one test
only (Supplementary Table 4). Men attending at least one
screening round had, after correction for nonattendance, a
PCa mortality reduction of 25%, and those who attended at
least two screening rounds had a decrease of 48% assuming
no effect of one-time screening. This model may explain the
large differences in PCa mortality reduction observed
between the centres within ERSPC, but other explanations
may also contribute, for example, the rate of opportunistic
screening in the control group (eg, Finland) [25]. This report
shows that cancers detected in round 1 have a poorer
prognosis, but this is partly due to the ERSPC study design
where men started screening in various age cohorts with a
median age of 60 yr at randomisation. Older men screened
for the first time showed a higher risk of being diagnosed
with incurable disease [26]. In a running screening
programme, men are invited from earlier age (50–55 yr),
and the risk of missing the “window of cure” is probably
lower. Furthermore, randomised screening trials will
underestimate the true effect of an effective population-
based screening programme [27].
Our study has limitations including heterogeneous
populations with different background risks between
centres, possibly influencing the results. Another limitation
is the increased uptake of opportunistic screening in
Europe, which could underestimate the true effects of
screening.
5. Conclusions
This 16-yr report from ERSPC shows that the absolute effect
of screening on PCa mortality increases with longer follow-
up. The excess PCa incidence among screened men is
decreasing but is still rather high. The PCa mortality
reduction seems to be related to the duration of screening,
and a one-time screening test is suggested to have little or
no effect on PCa mortality due to a prevalence pool of more
advanced disease in which treatment is unlikely to provide
major benefits.
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